Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3473 for Persistent or Chronic Primary ITP
NCT07083739Phase 2Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3473 in primary immune thrombocytopenia (ITP), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
TQB3473
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07083739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083739.